Seres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapy [MarketWatch]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: MarketWatch
Seres Therapeutics Inc. shares dropped 7.4% in premarket trade on Monday after the company said its microbiome therapy intended for ulcerative colitis received an orphan drug designation from the Food and Drug Administration. The therapy, SER-287, has been studied in a phase 1b trial in patients with mild-to-moderate ulcerative colitis who were failing current therapies, and the FDA reviewed those results in the orphan drug determination, Seres said. SER-287 is a cutting-edge therapy that is taken orally and contains "a consortium of live bacterial spores" to work on the microbiome, or microorganisms like bacteria and viruses in the body. Typically a company's shares rise on an orphan drug designation, which is intended for products that treat a rare disease, and provides various development incentives, including seven years of marketing exclusivity, tax credits and the waiver of some regulatory fees. But Seres shares have dropped before on seemingly-positive results: when the company
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTBusiness Wire
- Global Microbiome Manufacturing Industry Research 2024: A $187 Billion Market by 2035 with Close to 170 Trials Evaluating Microbiome Therapeutics to Treat Infectious Diseases and Oncological Disorders [Yahoo! Finance]Yahoo! Finance
- Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
MCRB
Earnings
- 11/2/23 - Beat
MCRB
Sec Filings
- 4/8/24 - Form 4
- 4/8/24 - Form 4
- 4/8/24 - Form 4
- MCRB's page on the SEC website